SCHEMBL26110237

SCHEMBL26110237

COC(=O)c1cc(OC)c2nc(Cl)c(Br)cc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 2/20 0.44
CYP3A4 P08684 1/20 0.42
PTPN11 Q06124 1/20 0.39
MAPT P10636 3/20 0.39
CNR2 P34972 1/20 0.38
KMT2A Q03164 3/20 0.38
GLA P06280 1/20 0.38
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
APOBEC3A P31941 1/20 0.36
HTT P42858 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
GAA P10253 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30596874 1.00 KDM4E (0.44) KDM4EALDH1A1CYP3A4PTPN11MAPT
SCHEMBL25116003 0.87 CA12 (0.46) ALDH1A1CNR2KMT2ACA12CA1
SCHEMBL25114393 0.87 KDM4E (0.47) KDM4EALDH1A1CYP3A4PTPN11MAPT
SCHEMBL23930154 0.84 KDM4E (0.45) KDM4EALDH1A1CYP3A4PTPN11MAPT
SCHEMBL30596879 0.84 KDM4E (0.45) KDM4EALDH1A1CYP3A4PTPN11MAPT
SCHEMBL23905305 0.83 KDM4E (0.44) KDM4EALDH1A1CYP3A4PTPN11MAPT
SCHEMBL30596878 0.83 KDM4E (0.44) KDM4EALDH1A1CYP3A4PTPN11MAPT
SCHEMBL26113416 0.83 KDM4E (0.44) KDM4EALDH1A1CYP3A4PTPN11MAPT
SCHEMBL31323187 0.83 KDM4E (0.44) KDM4EALDH1A1CYP3A4PTPN11MAPT
SCHEMBL31323204 0.79 ALDH1A1 (0.45) KDM4EALDH1A1CYP3A4PTPN11MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368659-A1 Antiviral Heterocyclic Compounds ENANTA PHARM INC (US) 2025-12-04 US disclosed
US-12358921-B2 Antiviral heterocyclic compounds ENANTA PHARMACEUTICALS, INC. (US) 2025-07-15 US disclosed
US-20230357258-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ENANTA PHARMACEUTICALS, INC. 2023-11-09 US disclosed
WO-2023196454-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ENANTA PHARMACEUTICALS, INC. (US) 2023-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357258-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ACE, HPRT1, ACE2 KDM4E 1580/4885ALDH1A1 2104/4885CYP3A4 130/4885
US-12358921-B2 Antiviral heterocyclic compounds ACE, HPRT1, ACE2 KDM4E 1580/4885ALDH1A1 2104/4885CYP3A4 130/4885
US-20250368659-A1 Antiviral Heterocyclic Compounds ACE, HPRT1, ACE2 KDM4E 1580/4885ALDH1A1 2104/4885CYP3A4 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.